Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Technology assessment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Technology assessment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Technology assessment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Lymphomas are blood cancers that develop in the lymphatic system and are divided into Hodgkin lymphoma and non-Hodgkin lymphomas (NHL). NHLs are categorized as B-cell, Tcell, or natural killer/T-cell lymphoma, depending on the cell implicated in the disease. While B-cell NHLs display a wide range of clinical behaviours, there are several subtypes that have a roughly similar clinical course and are treated in a similar manner. These subtypes include diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. In Canada, NHL accounts for 83% of all cases of lymphomas. In this context, axicabtagene ciloleucel is a chimeric antigen receptor (CAR) T-cell therapy that has been approved by the FDA for use in "adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma." As Health Canada approval for axicabtagene ciloleucel is pending, the final indication remains to be confirmed; however, based on the available evidence and existing approvals for this therapy (i.e., by the FDA and the European Union), potentially eligible indications are these types of relapsed or refractory large B-cell lymphomas: DLBCL, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Technology assessment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book serves as a comprehensive toolkit for evaluating and scaling digital innovations in tuberculosis care. Developed by the World Health Organization, it provides a structured approach to implement digital technologies across the TB continuum of care. The guide includes modules on research preparation, developing objectives, research methods, data management, and application of knowledge. Aimed at researchers and healthcare professionals, it emphasizes the importance of stakeholder analysis and ethical considerations in health technology. The book is intended to aid low and middle-income countries in utilizing digital tools to enhance TB treatment outcomes.

Tuberculosis. --- Technology assessment. --- Tuberculosis --- Technology assessment